STRO

Sutro Biopharma Stock Analysis

AI Rating

Neutral
  • Quality8/10
  • Growth↓ 0/10
  • Momentum↑ 9/10
Sutro Biopharma sales and earnings growth
STRO Growth
Low
  • Revenue Y/Y↓ -34.36%
  • EPS Y/Y↓ -62.11%
  • FCF Y/Y↓ -106.15%
Sutro Biopharma gross and profit margin trends
STRO Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -205.20%
  • ROIC↓ -202.80%
Sutro Biopharma net debt vs free cash flow
STRO Risk
Great
  • Debt / Equity↓ -0.2
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -303.2

Sutro Biopharma stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗